What Is BK Viremia? Symptoms, Causes, and Management

BK viremia means that BK polyomavirus, a small DNA virus carried by most adults, is circulating in the bloodstream at detectable levels. For a healthy person this rarely matters, because an intact immune system keeps the virus dormant. The condition becomes a serious clinical problem almost exclusively when the immune system is deliberately suppressed, most commonly after a kidney transplant or a bone marrow transplant. Left unchecked, BK viremia can progress to kidney damage, hemorrhagic cystitis, or graft loss, which makes screening, early detection, and careful management of immunosuppression central to transplant care.

A Virus Most People Already Carry

BK polyomavirus is one of several human polyomaviruses that infect people during childhood, usually without causing any noticeable illness. Studies of general populations consistently show that the majority of adults carry antibodies against it. In a Czech population study, about 69% of people tested positive for BK virus antibodies, with the highest rates in teens and young adults.¹ A Finnish cohort tracked over three years showed seroprevalence above 94% regardless of the antibody threshold used.² After the initial infection, the virus settles into the kidneys and urinary tract, where it stays dormant inside the lining cells of the renal tubules.³

Dormant BK virus is harmless. The trouble starts only when something weakens the immune surveillance that keeps the virus in check. For the vast majority of people, that “something” is transplant-related immunosuppression.

From Virus in the Urine to Virus in the Blood

After a kidney transplant, BK virus reactivation follows a fairly predictable cascade. The virus wakes up in the urinary tract first, shedding into the urine. This stage is called viruria, and it happens in roughly 30 to 50% of kidney transplant recipients. Of those with viruria, about one-third go on to develop viremia, meaning virus has crossed into the bloodstream in measurable quantities.⁴ That progression from viruria to viremia is the critical step that transplant teams watch for, because persistent or high-level viremia can lead to BK virus-associated nephropathy, which, without intervention, develops in somewhere between 1 and 10% of kidney transplant recipients and threatens the transplanted kidney itself.

In bone marrow transplant recipients the picture looks different. The main BK-related complication there is hemorrhagic cystitis, a painful inflammation of the bladder lining that causes bleeding into the urine. Risk factors include high-level virus shedding in the urine, intensive conditioning treatments before transplant, and graft-versus-host disease.⁵

Why BK Viremia Is Often Silent

One of the frustrating things about BK viremia is that it often produces no symptoms at all, at least not early on. The clinical presentation ranges from completely asymptomatic viremia all the way to noticeable kidney dysfunction.⁶ In a pediatric study, a third of children with confirmed viremia showed no symptoms whatsoever; the rest had rising creatinine levels detected only through routine lab tests.⁷

When symptoms do appear, they tend to be indirect. A transplant recipient might notice decreased urine output, swelling, or fatigue, all signs that the transplanted kidney is struggling. But these same symptoms overlap with organ rejection and other post-transplant problems, so they cannot reliably point to BK virus on their own. That is exactly why transplant programs do not wait for symptoms. They screen proactively.

Screening and Diagnosis

Most transplant centers screen kidney recipients for BK virus at regular intervals during the first one to two years after surgery. The primary tool is a blood test that measures the amount of viral DNA using a technique called quantitative PCR. Plasma PCR outperforms urine-based PCR and urine cytology in terms of how specifically it predicts actual kidney involvement.⁸

An older and cheaper screening method involves looking for “decoy cells” in the urine under a microscope. These are virus-infected cells shed from the urinary tract that have distinctively enlarged, dark nuclei. Decoy cell screening is sensitive, picking up around 86 to 96% of cases depending on the study and the threshold used.⁹ However, it is less specific than plasma PCR, meaning it picks up some false alarms. Research has shown that using a higher threshold for decoy cell counts can improve specificity dramatically, up to about 99.7% for predicting actual nephropathy when more than 20 decoy cells are found per ten high-power fields.¹⁰

When plasma viral levels rise above a concerning threshold, a kidney biopsy usually follows. On biopsy, pathologists look for characteristic changes in the kidney cells and confirm the virus with special stains for a protein called SV40 large T antigen.¹¹ The commonly used cutoff for concerning plasma viral load has been 10,000 copies per milliliter (or 4 log10), but a single-center experience found that about 35% of patients with biopsy-confirmed BK nephropathy never reached that cutoff, and some of those patients lost their grafts.¹² That finding has pushed some programs to investigate the kidney even when viral levels are below the traditional threshold.

Risk Factors for Developing BK Viremia

A systematic review identified eight factors that increase the likelihood of BK viremia in kidney transplant recipients: use of tacrolimus-based immunosuppression, receiving a kidney from a deceased donor, being male, having had a previous transplant, older age at transplant, use of a ureteral stent, delayed graft function, and episodes of acute rejection.¹³ Among these, the degree of immunosuppression is probably the single biggest driver. One study found that patients whose average tacrolimus trough levels exceeded 10 ng/mL had dramatically higher rates of BK virus shedding in the urine compared to those with levels below 8 ng/mL.¹⁴

Immunological mismatches between donor and recipient also matter. Higher HLA mismatch, Afro-Caribbean ethnicity, and having pre-existing antibodies against many different donor types (a high panel-reactive antibody level) have each been tied to increased risk.¹⁵ On the donor side, age plays a role: older donors are more likely to transmit virus that leads to viruria in the recipient.¹⁶

Complications Beyond the Kidney

When BK viremia goes uncontrolled, the most feared complication in kidney recipients is BK nephropathy, where the virus directly damages the transplanted kidney. On biopsy, kidney cells show enlarged nuclei stuffed with viral material, and in some cases the virus spreads to the glomeruli, the tiny filtering units of the kidney.¹⁷ When the glomeruli are affected, crescent-shaped scars can form, a sign of serious inflammatory damage.

BK virus also causes problems in the urinary plumbing. Ureteral stenosis, a narrowing of the tube connecting the kidney to the bladder, can develop when the virus infects and destroys the lining of the ureter. This damage is initially focal, then leads to inflammation, ulceration, and ultimately scarring that blocks urine flow. The clinical sign is often painless swelling of the kidney on ultrasound, discovered when kidney function starts to decline.¹⁸ The same problem has been documented in bone marrow transplant recipients, where inflammation and bleeding in the upper urinary tract caused ureteral obstruction.¹⁹

Managing BK Viremia

There is no antiviral drug approved specifically for BK virus. The cornerstone of management has been the same for decades: reduce immunosuppression so the patient’s own immune system can fight the virus. But that creates an obvious dilemma. Too much immunosuppression lets the virus thrive. Too little risks rejection of the transplanted organ. Transplant teams walk this line constantly, and there is no standardized protocol for exactly how to do it.²⁰

The practical approach usually involves reducing the dose of one or more immunosuppressive drugs. However, the specifics matter. One study found that completely stopping mycophenolate mofetil (a common anti-rejection drug) rather than just reducing it was strongly linked to acute rejection, and that cutting tacrolimus levels by more than 20% also increased rejection risk significantly.²¹ A multicenter analysis found that switching to leflunomide (sometimes used as an alternative immunosuppressant with possible antiviral properties) reduced viral burden but roughly doubled the odds of rejection.²² In short, every adjustment is a trade-off.

For patients who do not respond to immunosuppression reduction alone, intravenous immunoglobulin (IVIG) has been tried as an add-on treatment. A systematic review found that IVIG appeared effective at clearing viremia and treating nephropathy, and preemptive use in high-risk patients may reduce the chance of developing viremia in the first place. However, IVIG did not clearly improve long-term kidney function, since creatinine levels did not consistently improve across studies.²³ One case series of 30 patients who had failed initial management showed that IVIG cleared viremia in 90% of them, with a 12-month graft survival rate of about 97%.²⁴ Still, the overall evidence for IVIG comes mostly from case series and retrospective studies rather than large randomized trials.²⁵

What Happens When the Graft Is Lost

BK nephropathy can lead to graft failure. In patients who develop nephropathy, death-censored graft survival is substantially worse than in transplant recipients without the condition, and this is even more pronounced when BK nephropathy occurs alongside episodes of acute rejection.²⁶ The rates of graft loss vary across studies, influenced by how early the diagnosis is made and how aggressively immunosuppression is adjusted. One cohort using a steroid-free maintenance regimen reported graft loss in about 76% of patients diagnosed with BK nephropathy, with 12-month graft survival after diagnosis at roughly 22%.²⁷ These numbers are sobering, but they represent a specific clinical context and should not be taken as universal outcomes.

The good news for patients who do lose a graft to BK nephropathy is that re-transplantation works well. An analysis of the national transplant database found that patients retransplanted after BK-related graft loss had a three-year graft survival rate of about 94%, and their outcomes were comparable to or better than patients retransplanted for other reasons like acute rejection or disease recurrence.²⁸ A more recent study confirmed this, showing five-year graft survival of about 91% in the BK retransplant group, with no significant difference in rejection rates or patient survival compared to non-BK retransplants.²⁹ The clear takeaway is that a history of BK-related graft loss should not disqualify someone from receiving another transplant.

Virus-Specific T Cells as an Emerging Treatment

Because the root problem in BK viremia is that the patient’s immune system cannot fight the virus adequately, one logical solution is to supply the missing immune cells directly. Virus-specific T-cell therapy does exactly that. T cells trained to recognize BK virus are grown in the lab, either from the transplant donor’s blood or from a bank of pre-screened healthy donors, and then infused into the patient.

Early results have been encouraging. A study of 41 transplant recipients (mostly bone marrow transplants) treated with BK-specific T cells between 2017 and 2019 reported an overall response rate of 86% in patients treated for viremia alone, and 100% in those treated for hemorrhagic cystitis.³⁰ A clinical trial using “off-the-shelf” third-party BK virus-specific T cells in 59 patients with hemorrhagic cystitis after bone marrow transplant found that about 82% of evaluable patients had responded by day 45, with no cases of severe graft-versus-host disease or infusion-related toxicity.³¹ The ability to use banked cells from unrelated donors rather than needing to grow cells from each patient’s own donor is a significant practical advantage, and this approach could eventually become part of the standard toolkit for managing BK virus in transplant patients.

Immune Monitoring to Guide Treatment Decisions

One of the persistent challenges in managing BK viremia is knowing when to act and how far to go. Viral load numbers tell you how much virus is circulating, but they do not tell you how well the patient’s immune system is actually fighting it. Two patients with the same viral load can have very different trajectories depending on their anti-BK immune response.

A lab test called the ELISPOT assay measures how many of a patient’s T cells respond to BK virus proteins by producing interferon-gamma, an immune signaling molecule. Research has found that transplant recipients who successfully cleared their viremia had higher ELISPOT results than those whose viremia persisted. Patients who went on to develop BK nephropathy had lower ELISPOT results than those who did not.³² A systematic review concluded that the ELISPOT assay is a useful tool for risk assessment and, when combined with viral load data, may help guide how aggressively to adjust immunosuppression.³³ The idea is that a patient with rising viral levels but a strong immune response might tolerate a smaller reduction in immunosuppression than someone whose immune system shows little activity against the virus.

BK Virus in Children After Kidney Transplant

Children who receive kidney transplants face BK virus reactivation too, and the numbers are broadly similar to adults. Screening studies of pediatric recipients have found BK virus in the urine of roughly 19 to 26% of children, in the blood of about 5 to 13%, and biopsy-confirmed nephropathy in 2 to 8%.³⁴ Children present an additional challenge because many first encounter BK virus around the time of transplant, meaning they may be dealing with a primary infection rather than reactivation of a latent one. Children also tend to receive more aggressive immunosuppression relative to their body size, and their immune systems are still maturing, both factors that can affect how the virus behaves. Screening protocols for children generally mirror those used in adults, with regular viral load testing during the first year or two after transplant.

How Viral Genetics Shape the Outcome

Not all BK viruses behave identically. The virus carries a stretch of DNA called the noncoding control region that acts as an on-off switch for viral replication. In most healthy carriers, the virus circulates in a quiet “archetype” form. But mutations and rearrangements in this control region can create more aggressive variants that replicate faster and cause more tissue damage.³⁵ Lab experiments have shown that even small changes, like swapping or duplicating a single binding site in this region, can shift the virus toward faster replication.³⁶ Whether a patient’s virus has these rearranged variants may eventually help predict who is at highest risk for progression, though this kind of viral genotyping is not yet part of routine clinical practice.